Delivery Order SPE2DB24D2205-SPE2DB25FEDLU
- Not listed
- The Defense Logistics Agency awarded a $8,222.46 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 15, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a $38,034.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract, which is not set-aside and was competitively awarded, requires completion by June 18, 2025, with performance to be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $9,217.60 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 ml syringes on April 23, 2025, with completion targeted for April 24, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the contractor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order valued at $5,002.32 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes (4 mL units). This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 29, 2025. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $5,938.04 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 ml syringes. This firm fixed price delivery order, issued on November 6, 2025, with an ultimate completion date of November 7, 2025, represents a medical supply procurement under a competitive, non-set-aside award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $3,614.94 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion by June 2, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Monovisc 88 mg/4 mL syringes with a ceiling value of $6,256.75. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is due for completion by April 25, 2025, and will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location. As a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a $8,563.34 delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Monovisc 88 mg/4 ml syringes. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of November 10, 2025. The product will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a $7,062.93 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This competitive award, which is non-set-aside, will be performed at the contractor's Conshohocken, Pennsylvania location with an ultimate completion date of July 15, 2025. The contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $14,829.77 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes on September 24, 2025, with completion expected by September 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Monovisc is a viscosupplement injection used in orthopedic and rheumatological...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEDLUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,885.99 to AmerisourceBergen Drug Corp for the supply of Monovisc 88 mg/4 mL syringes. This non-competitive, firm fixed-price delivery order was awarded on June 10, 2025, with an ultimate completion date of June 11, 2025. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across military and veteran healthcare systems. The parent IDC enables the company to supply a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains to support military healthcare programs worldwide. The Monovisc product—a hyaluronic acid-based intra-articular injection used for osteoarthritis treatment—represents one of many pharmaceutical commodities delivered through this flexible contract vehicle to support the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 6/10/25 |